Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

MAB1794

Sigma-Aldrich

Anti-Human B cells (CD19) Antibody, clone FMC63

clone FMC63, Chemicon®, from mouse

Szinonimák:

B-lymphocyte Surface Antigen B4

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

UNSPSC kód:
12352203
eCl@ss:
32160702
NACRES:
NA.43
klón:
FMC63, monoclonal
application:
FACS
IF
faj reaktivitás:
human
technika/technikák:
flow cytometry: suitable
immunofluorescence: suitable
citations:
11

biológiai forrás

mouse

Minőségi szint

antitest forma

purified antibody

antitest terméktípus

primary antibodies

klón

FMC63, monoclonal

faj reaktivitás

human

gyártó/kereskedő neve

Chemicon®

technika/technikák

flow cytometry: suitable
immunofluorescence: suitable

izotípus

IgG2a

NCBI elérési szám

UniProt elérési szám

kiszállítva

wet ice

célzott transzláció utáni módosítás

unmodified

Géninformáció

human ... CD19(930)

Általános leírás

BIOCHEMISTRY:

p I = 7.0

Egyediség

This specificity of this antibody is equivalent to that of CD19 monoclonal antibodies (Zola et al., 1988, 1989), based on comparative studies, antigen recognition and positive reaction with a CD19 transfected cell line. It detects a 96 kD single chain glycoprotein on the surface of human B lineage cells, including pre-B cells. B cells can be detected in peripheral blood and tissues. The antibody reacts with most B cell malignancies including chronic lymphocytic leukemia and most lymphomas, but not multiple myeloma.

Cell reactivity:

Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.

Clinical:

B cell chronic lymphocytic leukemia (B-CLL) +

Pro lymphocytic leukemia (PLL) +

Hairy cell leukemia (HCL) +

Common acute lymphoblastic leukemia (CALL) +

Pre-B acute lymphoblastic leukemia (pre-B-ALL) +

NULL-acute lymphoblastic leukemia (NULL-ALL) +

T common lymphocytic leukemia (T-CLL) -

Immunogén

Raji cells

Alkalmazás

Research Category
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
This Anti-Human B cells CD19 Antibody, clone FMC63 is validated for use in FC, IF for the detection of CD19.
This antibody is useful for enumerating normal B lymphocytes and typing B cell malignancies by flow cytometry and immunofluorescence.

SUGGESTED USAGE DILUTION

Flow cytometry and Indirect Immunofluorescence 1:25

Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.

Kapcsolódás

Replaces: CBL141

Fizikai forma

Format: Purified
Purified from mouse ascitic fluid. The antibody is supplied in 25 mM Tris-HCl buffer, 0.4 M NaCl, pH 8.0, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.

Tárolás és stabilitás

Store at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.

WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.

Egyéb megjegyzések

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Jogi információk

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Jogi nyilatkozat

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Nem találja a megfelelő terméket?  

Próbálja ki a Termékválasztó eszköz. eszközt

Tárolási osztály kódja

12 - Non Combustible Liquids

WGK

WGK 2

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Stephanie N Shishido et al.
Journal for immunotherapy of cancer, 12(2) (2024-02-14)
Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response
Ye Lin et al.
Frontiers in neurology, 13, 808322-808322 (2022-03-18)
Myasthenia gravis (MG) is an autoimmune disease mediated by B cells secreting autoantibodies. Regulatory B (Breg) cells confirmed to have an immunosuppressive function play an important role in many autoimmune diseases. However, what about the changes in Breg cells in
Fabiana Zappala et al.
Science advances, 8(18), eabn4613-eabn4613 (2022-05-07)
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We
Christine Ambrose et al.
PloS one, 16(3), e0247701-e0247701 (2021-03-19)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy
Xing Du et al.
Cancer research, 68(15), 6300-6305 (2008-08-05)
B-cell malignancies routinely express surface antigens CD19 and CD22. Immunotoxins against both antigens have been evaluated, and the immunotoxins targeting CD22 are more active. To understand this disparity in cytotoxicity and guide the screening of therapeutic targets, we compared two

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással